Trial Profile
A randomized, cross-over study analyzing optimization of Albuminuria lowering treatment by rotation to different drug classes
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 25 Jan 2023
Price :
$35
*
At a glance
- Drugs Baricitinib (Primary) ; Empagliflozin (Primary) ; Linagliptin (Primary) ; Telmisartan (Primary)
- Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
- Focus Therapeutic Use
- 18 Jan 2023 Results published in the Diabetes Care
- 29 Jul 2022 New trial record
- 07 Jun 2022 Primary endpoint has been met. (difference in UACR response between the first and second exposure to the best performing drug, versus the difference in UACR response between the best performing drug and the other three drugs),as per Results presented at the 82nd Annual Scientific Sessions of the American Diabetes Association